The Hu-M? CIEA NOG Mouse?: A Novel Preclinical Platform for Testing the Efficacy of Therapeutics Against Cancer and Infectious Diseases

摘要

As checkpoint blockade becomes a promising therapeutic avenue for cancer therapy, current preclinical models are not able to recapitulate the antitumor immune responses mediated by checkpoint blockade therapies. This is partly because of the inherent differences between the mouse and the human immune systems. The systematic production and generation of "humanized" mice is critical in order to address the high unmet need for a robust preclinical platform for testing immuno-therapies directed against cancer in the context of a human immune system. HuMurine's Hu-M? mice are constructed by injecting pre-qualified human CD34+ hematopoietic progenitor cells (HPCs) into newborn NOG mice resulting in stable multi-lineage human hematopoiesis at 10-15 weeks post engraftment.